Société Générale — M&A Activity 2021

Jun 1, 2021

National Storage Mechanism | Additional information

RNS Number : 2839A

Societe Generale SA

01 June 2021

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	UDG Healthcare plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	€0.05 ordinary shares
Date of dealing	28/05/2021

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
Number	(%)	Number	(%)
(1) Relevant securities	3,593,635	1.43	205,320	0.08
(2) Derivatives (other than options)	200,467	0.08	0	0.00
(3) Options and agreements to purchase/sell	0	0.00	0	0.00
Total	*3,854,102	*1.53	205,320	0.08

* Include the holding of 60,000 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit GBP (Note 5)
Purchase	666	10.58
Purchase	2,177	10.58
Purchase	1,276	10.58
Purchase	696	10.58
Purchase	285	10.56
Purchase	221	10.56
Purchase	200	10.56
Purchase	155	10.56
Purchase	565	10.56
Purchase	429	10.58
Purchase	57	10.57
Purchase	200	10.57
Purchase	56	10.57
Purchase	1,142	10.56
Purchase	1,213	10.57
Purchase	428	10.56
Purchase	24	10.57
Purchase	194	10.57
Purchase	407	10.58
Purchase	429	10.57
Purchase	454	10.58
Purchase	703	10.59
Purchase	283	10.59
Purchase	827	10.58
Purchase	1,879	10.58
Purchase	1,179	10.58
Purchase	200	10.58
Purchase	182	10.58
Purchase	56	10.58
Purchase	1,286	10.58
Purchase	1,140	10.58
Purchase	314	10.57
Purchase	227	10.56
Purchase	720	10.56
Purchase	645	10.56
Sale	97,634	10.58
Sale	102,833	10.58
Total Purchases	20,915
Total Sales	200,467

Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit GBP (Note 5)
CFD	Opening long	97,634	10.58
CFD	Opening long	102,833	10.58

(b)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(c)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements, or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any

relevant securities to which any derivative referred to on this form is referenced. If none, this

should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            No

Date of disclosure	31/05/2021
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEWPUQPAUPGUCG